Otsuka agreed to buy Transcend Therapeutics in a deal valued at about $1.2 billion, including roughly $700 million upfront, adding to a drug class designed to deliver psychedelic-like therapeutic benefits without the trip. The acquisition further consolidates Otsuka’s position in neuropsychiatric development. For the industry, the move signals continued payer- and regulator-facing investment in non-intoxicating mechanisms and differentiated CNS assets. Integration planning will determine how quickly Otsuka can advance Transcend’s programs toward pivotal readouts and potential label expansion. The market will watch the specific clinical programs inside Transcend that define the acquisition’s value and the expected path to late-stage catalysts.